AR056520A1 - Uso de inhibidores del intercambiador de na+/ h+, subtipo 5 (nhe5) para mejorar la memoria - Google Patents
Uso de inhibidores del intercambiador de na+/ h+, subtipo 5 (nhe5) para mejorar la memoriaInfo
- Publication number
- AR056520A1 AR056520A1 ARP060104074A ARP060104074A AR056520A1 AR 056520 A1 AR056520 A1 AR 056520A1 AR P060104074 A ARP060104074 A AR P060104074A AR P060104074 A ARP060104074 A AR P060104074A AR 056520 A1 AR056520 A1 AR 056520A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- carbon atoms
- zero
- alkyl
- cycloalkyl
- Prior art date
Links
- 102000050381 Na+/H+ exchanger Human genes 0.000 title abstract 2
- 108091006654 SLC9A5 Proteins 0.000 title abstract 2
- 102100029973 Sodium/hydrogen exchanger 5 Human genes 0.000 title abstract 2
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 206010027175 memory impairment Diseases 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Uso de inhibidores del intercambiador de Na+/H+, subtipo 5 (NHE5) para producir un medicamento para el tratamiento de trastornos neurodegenerativos, deterioros de la memoria y trastornos de demencia, y para mejorar la memoria. Reivindicacion 1: Uso de un compuesto de formula (1), en la cual los significados son: R1, R2, R3 y R4, de manera independiente uno de otro, hidrogeno, F, Cl, Br, I, CN, NO2 o R11-(CmH2m)-An-; m es cero, 1, 2, 3 o 4; n es cero o 1; R11 es hidrogeno, metilo o CpF2p+1; A es oxígeno, NH, N(CH3) o S(O)q; p es 1, 2 o 3; q es cero, 1 o 2; R5 es hidrogeno, alquilo con 1, 2, 3, 4, 5 o 5 átomos de carbono o cicloalquilo con 3, 4, 5, o 6 átomos de carbono; R6 es hidrogeno, OH, F, CF3, alquilo con 1, 2, 3, o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; R7 y R8, son, de manera independiente uno de otro, hidrogeno, F, Cl, Br, CN, CO2R12, NR13R14 o R16-(CmmH2mm)-Enn-; R12 es hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono; R13 y R14, de manera independiente uno de otro, hidrogeno, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; o R13 y R14, forman, con el átomo de nitrogeno al que están unidos, un anillo de 4, 5, 6 o 7 miembros, en el que un grupo CH2 puede estar reemplazando por NR15, S u oxígeno; R15 es hidrogeno, alquilo con 1, 2, 3, o 4 átomos de carbono o cicloalquilo con 3, 4, 5 o 6 átomos de carbono; mm es cero, 1, 2, 3 o 4; nn es cero o 1; R16 es hidrogeno, metilo o CppF2pp+1; E es oxígeno o S(O)qq; pp es 1, 2 o 3; qq es cero, 1 o 2; y también sus sales farmacéuticamente aceptables; para producir un medicamento para el tratamiento de trastornos neurodegenerativos, deterioros de la memoria y trastornos de demencia, y para mejorar la memoria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005044815A DE102005044815A1 (de) | 2005-09-20 | 2005-09-20 | Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056520A1 true AR056520A1 (es) | 2007-10-10 |
Family
ID=37102563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104074A AR056520A1 (es) | 2005-09-20 | 2006-09-18 | Uso de inhibidores del intercambiador de na+/ h+, subtipo 5 (nhe5) para mejorar la memoria |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080234317A1 (es) |
| EP (1) | EP1928458B1 (es) |
| JP (1) | JP2009508890A (es) |
| KR (1) | KR20080046676A (es) |
| CN (1) | CN101267822A (es) |
| AR (1) | AR056520A1 (es) |
| AT (1) | ATE424203T1 (es) |
| AU (1) | AU2006294137A1 (es) |
| BR (1) | BRPI0616196A2 (es) |
| CA (1) | CA2623472A1 (es) |
| DE (2) | DE102005044815A1 (es) |
| IL (1) | IL189915A0 (es) |
| TW (1) | TW200812584A (es) |
| WO (1) | WO2007033774A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2384318T1 (en) | 2008-12-31 | 2018-03-30 | Ardelyx, Inc. | MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| MX382203B (es) | 2013-04-12 | 2025-03-11 | Ardelyx Inc | Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir transporte de fosfato. |
| US10647679B2 (en) | 2015-03-15 | 2020-05-12 | Emory University | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto |
| UA126283C2 (uk) | 2017-01-09 | 2022-09-14 | Арделікс, Інк. | Сполуки, придатні для лікування розладів шлунково-кишкового тракту |
| JP2020505333A (ja) | 2017-01-09 | 2020-02-20 | アルデリックス， インコーポレイテッド | Ｎｈｅ媒介性アンチポートの阻害薬 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352688A (en) * | 1991-02-14 | 1994-10-04 | The Mount Sinai School Of Medicine Of The City University Of New York | Methods for the treatment of bradyphrenia in parkinson's disease |
| US5466696A (en) * | 1992-09-10 | 1995-11-14 | Warner Lambert Company | Tacrine and cytochrome P450 oxidase inhibitors and methods of use |
| JPH08217681A (ja) * | 1995-02-13 | 1996-08-27 | Lion Corp | 老人性痴呆症予防治療剤 |
| ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| WO2001032625A1 (en) * | 1999-11-03 | 2001-05-10 | Du Pont Pharmaceuticals Company | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| KR20080065707A (ko) * | 1999-11-03 | 2008-07-14 | 에이엠알 테크놀로지, 인크. | 4-페닐-치환 테트라히드로이소퀴놀린, 및 노르에피네프린과도파민과 세로토닌의 재흡수를 차단하기 위한 이의 용도 |
| WO2003033016A1 (en) * | 2001-10-16 | 2003-04-24 | Jenny Phipps | Use of neurotrophic factors for treating neurodegenerative diseases and cancer |
| DE10163914A1 (de) * | 2001-12-22 | 2003-07-03 | Aventis Pharma Gmbh | Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| US20050070601A1 (en) * | 2003-09-29 | 2005-03-31 | Creative Compounds, Llc | Psychostimulant Effects of Forskolin Including Anorexia |
| DE102005044817A1 (de) * | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
-
2005
- 2005-09-20 DE DE102005044815A patent/DE102005044815A1/de not_active Withdrawn
-
2006
- 2006-09-08 AT AT06791935T patent/ATE424203T1/de active
- 2006-09-08 EP EP06791935A patent/EP1928458B1/de not_active Withdrawn - After Issue
- 2006-09-08 WO PCT/EP2006/008771 patent/WO2007033774A2/de not_active Ceased
- 2006-09-08 JP JP2008531570A patent/JP2009508890A/ja not_active Withdrawn
- 2006-09-08 KR KR1020087006833A patent/KR20080046676A/ko not_active Withdrawn
- 2006-09-08 CN CNA2006800346408A patent/CN101267822A/zh active Pending
- 2006-09-08 BR BRPI0616196-0A patent/BRPI0616196A2/pt not_active Application Discontinuation
- 2006-09-08 CA CA002623472A patent/CA2623472A1/en not_active Abandoned
- 2006-09-08 AU AU2006294137A patent/AU2006294137A1/en not_active Abandoned
- 2006-09-08 DE DE502006003030T patent/DE502006003030D1/de active Active
- 2006-09-18 TW TW095134387A patent/TW200812584A/zh unknown
- 2006-09-18 AR ARP060104074A patent/AR056520A1/es unknown
-
2008
- 2008-03-04 IL IL189915A patent/IL189915A0/en unknown
- 2008-03-12 US US12/046,920 patent/US20080234317A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE102005044815A1 (de) | 2007-03-22 |
| AU2006294137A1 (en) | 2007-03-29 |
| ATE424203T1 (de) | 2009-03-15 |
| JP2009508890A (ja) | 2009-03-05 |
| KR20080046676A (ko) | 2008-05-27 |
| BRPI0616196A2 (pt) | 2011-06-14 |
| DE502006003030D1 (de) | 2009-04-16 |
| CA2623472A1 (en) | 2007-03-29 |
| US20080234317A1 (en) | 2008-09-25 |
| EP1928458A2 (de) | 2008-06-11 |
| CN101267822A (zh) | 2008-09-17 |
| WO2007033774A3 (de) | 2007-06-28 |
| EP1928458B1 (de) | 2009-03-04 |
| TW200812584A (en) | 2008-03-16 |
| WO2007033774A2 (de) | 2007-03-29 |
| IL189915A0 (en) | 2008-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
| ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
| ES2570745T3 (es) | Aza-heterociclos bicíclicos y su uso | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR067478A1 (es) | Compuestos derivados de morfolina pirimidina | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| CR10034A (es) | Derivados de oxadiazol | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| AR078833A1 (es) | Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3 | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR070479A1 (es) | Derivado heterociclico fusionado y su uso | |
| ES2570628T3 (es) | Nuevas arilamidas con sustitución imidazol | |
| PA8852101A1 (es) | Nucleótidos uracil ciclopropílicos | |
| AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| ES2570766T3 (es) | Derivados del 1-bencil-3-hidroximetilindazol y su utilización en el tratamiento de enfermedades basadas en la expresión de MCP-1 y CX3CR1 | |
| CO6241117A2 (es) | Derivados de n-(fenil) -n-morfolin-4-il-piridin -2-il) - -pirimidina-2, 4-diamina como inhibidores del ephb4 quinasa para el tratamiento de condiciones proliferativas | |
| AR062405A1 (es) | Derivados de isoindol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |